FDA Public Workshop Summary - Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs

Elizabeth O'Shaughnessy, Yuliya Yasinskaya, Cheryl Dixon, Karen Higgins, Jason Moore, Kellie Reynolds, Neil M. Ampel, David Angulo, Janis E. Blair, Antonino Catanzaro, John N. Galgiani, Edward Garvey, Royce Johnson, David J. Larwood, Gareth Lewis, Rob Purdie, John H. Rex, Lisa F. Shubitz, David A. Stevens, Stephen J. PageSunita J. Shukla, John J. Farley, Sumathi Nambiar

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Coccidioidomycosis is a fungal disease endemic to the southwestern United States, Mexico, and Central and South America. Prevalence rates are increasing steadily, and new endemic areas of Coccidioides are emerging. Standard treatment is often administered for months to decades, and intolerance to medications and treatment failures are common. No new treatments for coccidioidomycosis have been approved in the United States in nearly 40 years. On 5 August 2020, the US Food and Drug Administration convened experts in coccidioidomycosis from academia, industry, patient groups, and other government agencies to discuss the disease landscape and strategies to facilitate product development for treatment of coccidioidomycosis. This article summarizes the key topics concerning drug development for coccidioidomycosis presented by speakers and panelists during the workshop, such as unmet need, trial designs, endpoints, incentives, research and development support, and collaborations to facilitate antifungal drug development.

Original languageEnglish (US)
Pages (from-to)2061-2066
Number of pages6
JournalClinical Infectious Diseases
Issue number11
StatePublished - Jun 1 2022


  • antifungal drugs
  • coccidioidomycosis
  • drug development
  • rare diseases
  • valley fever

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'FDA Public Workshop Summary - Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs'. Together they form a unique fingerprint.

Cite this